Zobrazeno 71 - 80
of 214
pro vyhledávání: '"Alan Lau"'
Autor:
Alan Lau, Frances M. Richards, Christopher J. Minteer, Sandra Bernaldo de Quirós Fernández, Timothy Isaac Johnson, Duncan I. Jodrell, Daniel Kottmann, Charles R. Dunlop, Yann Wallez, Larissa S. Carnevalli
Publikováno v:
EBioMedicine
EBioMedicine, Vol 68, Iss, Pp 103396-(2021)
EBioMedicine, Vol 68, Iss, Pp 103396-(2021)
BackgroundChemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell cycle specificities of a number of
Autor:
Tudor Petreus, Elaine Cadogan, Mark J. O'Connor, Aaron Smith, Alan Lau, Venkatesh Pilla Reddy, Susan E. Critchlow, Lenka Oplustil O'Connor, Marianne Ashford, Gareth M. Hughes
Microphysiological in vitro systems are platforms for preclinical evaluation of drug effects and significant advances have been made in recent years. However, existing microfluidic devices are not yet able to deliver compounds to cell models in a way
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98c8fc7380d2bb361cbc3bc726a7432f
https://doi.org/10.21203/rs.3.rs-121081/v1
https://doi.org/10.21203/rs.3.rs-121081/v1
Autor:
Sandra Bernaldo de Quirós Fernández, Elaine Cadogan, Charles R. Dunlop, Alan Lau, Frances M. Richards, Timothy Isaac Johnson, Stephen T. Durant, Duncan I. Jodrell, Yann Wallez
Publikováno v:
British Journal of Cancer
BackgroundPersonalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183fe9697c845cda96628feea6a69fca
Selected peer-reviewed extended articles based on abstracts presented at the 8th Int.Conference on Composite Materials and Material Engineering, 13th Int.Conference on Advanced Materials Research, and 6th Int.Conference on Frontiers of Composite Mate
Autor:
Neil H. James, Alan Lau, Antonio Ramos-Montoya, Gemma N Jones, Giuditta Illuzzi, Paul W. G. Wijnhoven, Katarzyna Falenta, Rebecca L. Lloyd, Lucy H. Young, Zena Wilson, Jonathan Stott, Emma Dean, Christophe D. Chabbert
Publikováno v:
Oncogene
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at single-strand breaks, leading
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2baf3724e07bec854228e122b048829f
https://www.repository.cam.ac.uk/handle/1810/322860
https://www.repository.cam.ac.uk/handle/1810/322860
Autor:
James W.T. Yates, Yann Wallez, Charles R. Dunlop, Frances M. Richards, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Duncan I. Jodrell, Alan Lau, Sandra Bernaldo de Quirós Fernández
Publikováno v:
Molecular Cancer Therapeutics. 17:1670-1682
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard of care but shows very limited antitumor e
Autor:
Alan Lau, Ahrum Min, Kyung Hun Lee, Miso Lee, Do Youn Oh, Mark J. O'Connor, Seongyeong Kim, Debora Keunyoung Kim, Tae Yong Kim, Jin Won Kim, Hee Jun Kim, Hyemin Jang, Jeffrey L. Brown, Yaewon Yang, Yung-Jue Bang, Seock-Ah Im
Publikováno v:
Molecular Cancer Therapeutics. 16:566-577
Ataxia telangiectasia and Rad3-related (ATR) can be considered an attractive target for cancer treatment due to its deleterious effect on cancer cells harboring a homologous recombination defect. The aim of this study was to investigate the potential
Autor:
Jeffrey L. Brown, Jung-Eun Kim, Hee Jun Kim, Mark J. O'Connor, Alan Lau, Tae Yong Kim, Seock-Ah Im, Seongyeong Kim, Yaewon Yang, Yung-Jue Bang, Ahrum Min, Kyung Hun Lee, Hyemin Jang, Do Youn Oh, Miso Lee
Publikováno v:
International Journal of Cancer. 140:109-119
Ataxia telangiectasia and Rad3-related (ATR) proteins are sensors of DNA damage, which induces homologous recombination (HR)-dependent repair. ATR is a master regulator of DNA damage repair (DDR), signaling to control DNA replication, DNA repair and
Autor:
Niall M. B. Martin, Bastiaan Evers, Charlotte Knights, Janneke E. Jaspers, Jos Jonkers, Attilla Ting, Henry Brown, Keith W. Caldecott, Sven Rottenberg, Rajesh Odedra, Lenka Oplustil O'Connor, Robert Hugh Bradbury, Aaron Cranston, David Alan Rudge, Mark J. O'Connor, Marina Pajic, Louise J. Jones, Alan Lau, Stuart L. Rulten
Publikováno v:
Cancer Research. 76:6084-6094
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Publikováno v:
Small. 17:2007311
Graphene-based supercapacitors have been attracting growing attention due to the predicted intrinsic high surface area, high electron mobility, and many other excellent properties of pristine graphene. However, experimentally, the state-of-the-art gr